BASIS OF PRESENTATION AND SUMMARY OF ACCOUNTING POLICIES (Tables)

6 Months Ended

Mar. 31, 2020

BASIS OF PRESENTATION AND SUMMARY OF ACCOUNTING POLICIES

Schedule of operations and timing of revenue recognition

The following table presents revenues disaggregated by our business operations and timing of revenue recognition:

	Three Month Period Ended:
	March 31,		March 31,
	2020		2019
Research and development services (over-time)	$	286,598	$	593,588
Product and authentication services (point-in-time):
Supply chain		12,646		20,234
Asset marking		110,697		158,078
Large scale DNA production		142,532		6,568
Total	$	552,473	$	778,468

	Six Month Period Ended:
	March 31,		March 31,
	2020		2019
Research and development services (over-time)	$	653,431	$	1,092,117
Product and authentication services (point-in-time):
Supply chain		31,320		244,803
Asset marking		219,269		319,303
Large scale DNA production		281,972		6,568
Total	$	1,185,992	$	1,662,791

Schedule of opening and closing contract balances

The opening and closing balances of the Company’s contract balances are as follows:

		October 1,		March 31,		$
	Balance sheet classification	2019		2020		change
Contract liabilities	Deferred revenue	$	628,993	$	671,526	$	42,533

Schedule of anti-dilutive securities not included computation of net loss per share

	2020	2019
Warrants	2,121,755	422,136
Stock options	241,557	161,455
Secured convertible notes	70,963	104,112
	2,434,275	687,703